Market News
Latest news from Stock markets.
Novartis to Buy Biotech Excellergy for Up to $2 Billion
Novartis agreed to buy Excellergy, bulking up its immunology portfolio with a biotech company that specializes in treatments for food allergy and other diseases.
...keep reeding on wsj.com
TFI International: Too Risky, Or Ready To Recover?
TFI International is one of North America's largest transportation and logistics businesses operating across Canada, the US, and Mexico through 3 main segments: less-than-truckload, truckload, and logistics. The business generates more than 70% of its revenue from the United States, which gives it exposure to the largest freight market on the continent. The latest developments confirm two things: business conditions remain soft, but management is still pulling the right levers.
...keep reeding on seekingalpha.com
Novartis to buy U.S.-based biotech firm Excellergy for up to $2 billion
Swiss pharma company Novartis said on Friday it will acquire California-based biotech company Excellergy in a deal worth up to $2 billion.
...keep reeding on reuters.com
Chinese universities with military links bought Super Micro servers with restricted AI chips
Four Chinese universities, including two linked to the People's Liberation Army, bought Super Micro Computer servers with restricted AI chips over the past year, procurement data shows, even as the U.S. clamps down on sales of some advanced processors to China.
...keep reeding on reuters.com
Foreign investors pull a record $12 billion from Indian stocks, sparked by Iran war
Foreign investors are poised to withdraw a record $12 billion from Indian equities in March as the Iran war disrupts oil and gas supplies, squeezing the economy. With just two trading days left in the month, this March could be the worst monthly selloff by foreign investors, surpassing the previous record of 940 billion rupees in October 2024.
...keep reeding on cnbc.com
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
– Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of Novartis, with a total potential transaction value of up to $2 billion – – Exl-111 is a potentially first-in-class allergic trifunctional ECRI targeting the IgE axis and is currently in Phase 1 development – PALO ALTO, Calif., March 27, 2026 (GLOBE NEWSWIRE) -- Excellergy, a biotechnology company developing a novel class of allergy therapeutics, today announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments.
...keep reeding on globenewswire.com
Nebius: Massive AI Deals Drive Growth, But Dilution Risks Loom
Nebius Group advances with strategic partnerships, notably a $2B Nvidia investment and a $12B Meta contract, strengthening its growth trajectory. NBIS raises $4.6B via convertible notes but faces ongoing capital needs, with total estimated raises reaching $20.5B to support expansion. Despite high CapEx and dilution risk, the company targets substantial EBITDA margin improvement and expects strong operating cash flow inflection by 2027.
...keep reeding on seekingalpha.com
Exercise of Options
TORONTO, ON / ACCESS Newswire / March 27, 2026 / Sintana Energy Inc. (TSX-V:SEI)(AIM:SEI)(OTCQX:SEUSF) ("Sintana" or the "Company") announces that it has received a notice of exercise in respect of stock options over 800,000 common shares of no-par value each in the Company ("Common Shares"). The options are being exercised by Mr.
...keep reeding on accessnewswire.com
Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression - Exl-111 would complement existing Novartis portfolio in allergy with potential to improve both symptom control and convenience Basel, March 27, 2026 – Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody in Phase 1. The acquisition builds on deep Novartis expertise in IgE biology and a long-standing presence in allergic disease. Exl-111 is designed as a next-generation extension of validated biology established by anti-IgE therapy, with the potential to complement the Novartis existing allergy portfolio across a range of allergic conditions and patient settings. “Excellergy adds a differentiated next-generation anti-IgE program that builds on biology Novartis knows well, supported by preclinical evidence and early clinical pharmacokinetic data,” said Fiona Marshall, President of Biomedical Research at Novartis. “Exl-111 is designed to go beyond conventional anti-IgE therapy, with the potential to deliver faster and deeper suppression of IgE signaling as well as improved symptom control. This proposed acquisition strengthens our allergy portfolio and reflects our strategy of advancing innovative bold science to bring meaningful additional benefits to patients.” IgE is a central driver of multiple allergic diseases. Unlike conventional anti-IgE approaches, Exl-111 is designed to dissociate receptor-bound IgE with the potential to drive faster and deeper Fc epsilon RI alpha (FcεRIα) downregulation. Preclinical studies and early human pharmacokinetic data from ongoing Phase 1 evaluation support a differentiated profile, with evidence of sustained exposure consistent with its half‑life‑extended design. If confirmed clinically, this mechanism could support earlier symptom relief, stronger disease control, more convenient dosing and broader use across food allergy, chronic spontaneous urticaria, chronic inducible urticaria, allergic asthma and other IgE-mediated diseases, including potentially in pediatric populations. Transaction Details Under the terms of the agreement, Novartis will pay up to USD 2 billion in upfront and milestone payments to acquire Excellergy. The transaction is expected to close in H2 2026, subject to the satisfaction or waiver of customary closing conditions, including regulatory approvals. About Novartis Immunology At Novartis, we're advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we're committed to shaping what's next in Immunology. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” or similar expressions, or by express or implied discussions regarding: potential new products or programs, including Exl-111, potential new indications for existing products; potential product launches or potential future revenues from any such products; results of ongoing clinical trials; or potential future, pending or announced transactions, including the acquisition of Excellergy, Inc.; or potential future sales or earnings. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Exl-111 will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that the expected benefits or synergies from this transaction will be achieved in the expected timeframe, or at all, nor can there be any guarantee that Exl-111 will be commercially successful in the future. In particular, our expectations regarding Exl-111 or the transaction described in this press release could be affected by, among other things, the satisfaction of customary closing conditions including regulatory approvals, as well as uncertainties concerning: global healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; research and development of new products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products; our ability to realize the strategic benefits, operational efficiencies or opportunities expected from our external business opportunities; the development or adoption of new technologies, including artificial intelligence, and new business models; actual or potential legal proceedings, including regulatory actions or delays or government regulation related to the products and pipeline products described in this press release; safety, quality, data integrity, or manufacturing issues; major macroeconomic and geo- and socio-political developments, including the impact of any potential tariffs on our products or the impact of war in certain parts of the world; future demand for our products; and other risks and factors referred to in Novartis AG's most recently filed Form 20-F and in subsequent reports filed with, or furnished to, the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
...keep reeding on globenewswire.com
Apparel Group x Steve Madden Lead a GCC-Wide CSR Initiative with Leading NGOs to Support Children of Determination
DUBAI, United Arab Emirates, March 27, 2026 (GLOBE NEWSWIRE) -- During Ramadan, and at a time when compassion and unity matter more than ever, Apparel Group brought together leading NGOs across the region for a collaboration dedicated to supporting children of determination. Mobilising its platform alongside trusted partners including Al Jalila Foundation in the UAE, Down Syndrome Charitable Association in Saudi Arabia, Qatar Charity, the Ministry of Social Development in Bahrain, and the Committee of Zakah of Muttrah in Oman, the initiative reflected a collective commitment to meaningful giving, strengthening communities and extending support to children and families across the region.
...keep reeding on globenewswire.com
4 "All Weather" ETFs to Buy With $2,000 and Hold Forever
The global economic outlook is beginning to look shakier and equity markets have begun to decline. In these types of environments, risk management can protect your portfolio and get you through the tougher times.
...keep reeding on fool.com
Baozun: Look Past Mixed Results
I retain a 'Buy' rating for Baozun after analyzing its performance, outlook, and valuations. BZUN's 4Q25 financial disclosures were mixed, considering the revenue outperformance and below-expectations earnings. Management's FY2028 operating income target of CNY550 million implies a substantial 63% CAGR.
...keep reeding on seekingalpha.com
Designer Brands Guides For A Flat FY26 But Still Trades At 17x Adjusted Earnings
Designer Brands reported a weak Q4, with negative comps, flat retail sales, and operating losses despite improved gross margins. DBI's brand portfolio showed positive growth and profitability but remained a small contributor, while overall sales and comps contracted for the year. Guidance for 2026 calls for flat sales and adjusted EPS of $0.28–0.38, implying a 17x multiple on adjusted earnings with minimal GAAP profitability.
...keep reeding on seekingalpha.com
Tennant Company Investigated by the Portnoy Law Firm
LOS ANGELES, March 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tennant Company , (“ Tennant " or the "Company") ( NYSE : TNC ) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
...keep reeding on globenewswire.com
KKRT: Long-Dated Bond From KKR, Down -8% This Year
KKR & Co. Inc.'s 6.875% Subordinated Notes offer liquidity and transparency as exchange-listed baby bonds with a $25 par value. KKRT's long maturity (2065) and high duration (14 years) make it highly sensitive to credit spreads and market risk. Despite an -8% price decline YTD and a 7.3% current yield, we remain at 'Hold' until yields reach 7.5-7.6% to compensate for risk.
...keep reeding on seekingalpha.com
Micron Stock: Did the AI Memory Leader Just Peak?
Micron has fallen more than 20% since it reported a strong second-quarter earnings report last week. Google said a new algorithm could significantly reduce the need for AI storage.
...keep reeding on fool.com
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune diseases, today announced the pricing of its underwritten public offering of $200.0 million aggregate principal amount of its 2.50% convertible senior notes due 2032 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and its underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $20.00 per share (such offering, the “Equity Offering”).
...keep reeding on globenewswire.com
U.S. administration wants a quick deal with Iran: Barclays
Mitul Kotecha of Barclays sees no signs of an 'obvious off-ramp' between the U.S. and Iran despite the discussions. He says major central banks are turning hawkish, and sees 'pain' for countries who are energy importers.
...keep reeding on youtube.com
Colabor Group Inc. Provides Update on Its SISP
SAINT-BRUNO-DE-MONTARVILLE, Québec, March 26, 2026 (GLOBE NEWSWIRE) -- Colabor Group Inc. (TSX: GCL) (“Colabor” or the “Company”) provided today an update regarding its sale and investment solicitation process (“SISP”) conducted under the supervision of the Superior Court of Québec (Commercial Division) (the “Court”) and Raymond Chabot Inc., as Court-appointed monitor of the Company (the “Monitor”) in connection with the restructuring proceedings (the “CCAA Proceedings”) of the Company and certain of its subsidiaries, Transport Paul-Émile Dubé Ltée, Le Groupe Resto-Achats Inc. and Norref Fisheries Quebec Inc., instituted on January 8, 2026, under the Companies' Creditors Arrangement Act (Canada).
...keep reeding on globenewswire.com
Akeso Reports Full-Year 2025 Financial Results
HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business. Commercial Operations Enter a New Phase of Growth In 2025, Akeso achieved record commercial sales revenue of RMB3,033.1 million, a 51.48% year-on-year increase.
...keep reeding on prnewswire.com
J. M. Smucker: Punishment For Past Mistakes Shouldn't Last Forever (Rating Upgrade)
J. M. Smucker faces another year of asset impairments and underperformance in fiscal 2026. Despite a portfolio of iconic brands, SJM's recent capital allocation missteps have weighed heavily on results. The stock has declined 21% over five years, lagging both the consumer staples sector and the broader equity market.
...keep reeding on seekingalpha.com
BRP Inc. (DOO:CA) Q4 2026 Earnings Call Transcript
BRP Inc. (DOO:CA) Q4 2026 Earnings Call Transcript
...keep reeding on seekingalpha.com
Special Dividends Are Not Quite Enough To Make Bnccorp Appealing
BNCCORP is rated Hold, reflecting overvaluation concerns despite a history of sizable special dividends. BNCC trades at a 13.9x P/E and a PEG of 1.3, both above sector medians, with key performance ratios below peers. Recent special dividends total $22 per share since 2021, but payout timing is irregular and not guaranteed.
...keep reeding on seekingalpha.com
Nvidia Stock Has Gone Nowhere for 6 Months. What Will It Take for Shares to Go Higher?
Nvidia fiscal fourth-quarter revenue surged 73% year over year. The company's CEO recently highlighted a $1 trillion revenue forecast extending through 2027.
...keep reeding on fool.com
ACES India Enables Seamless 4G & 5G Connectivity at Noida International Airport Ahead of Launch
/PRNewswire/ -- ACES India today announced a key milestone in India's digital infrastructure journey, enabling seamless 4G and 5G connectivity at the upcoming
...keep reeding on prnewswire.com
Marketing and Communications Executive Who Has Transformed Brands Across Healthcare, Industrials, and Professional Services, Sarah McHugh, Joins Telesto to Lead Growth Services
/PRNewswire/ -- Telesto, a growth strategy and services firm, today announced that Sarah McHugh has joined the firm as its growth services leader. McHugh will
...keep reeding on prnewswire.com
Sunseeker Robotics stelt robotmaaiers van de X Gen 2-reeks voor in Amsterdam en brengt harmonie in de tuin tot leven
/PRNewswire/ -- Sunseeker Robotics, een wereldwijd merk voor slimme tuinoplossingen, gaf vandaag in TAETS - Building 41 in Amsterdam het startschot voor zijn
...keep reeding on prnewswire.com
Hikvision to unveil multidimensional AIoT ecosystem at Hannover Messe 2026, redefining industrial safety and smart manufacturing
/PRNewswire/ -- Hikvision, a global leader in AIoT solutions, is set to participate in Hannover Messe 2026, the world's premier industrial trade fair, taking
...keep reeding on prnewswire.com
Tech-Driven Restoration: Saving the World's Critically Endangered White-Headed Langur
Through decades of careful conservation efforts, the white-headed langur population has increased from just
...keep reeding on feeds.newsfilecorp.com
IVW: Valuation Plunged To A Multi-Year Low On War-Driven Selloff, Buy The Dip
I upgrade iShares S&P 500 Growth ETF from 'Hold' to 'Buy,' citing war-driven selloff and robust earnings growth driving valuations to multi-year lows. IVW's forward P/E has dropped to attractive levels, with tech sector earnings growth and mega-cap valuation corrections enhancing its rebound potential. The ETF's high beta and tech-heavy portfolio position it for sharp recovery, supported by historical post-war market rebounds and strong sector earnings forecasts.
...keep reeding on seekingalpha.com
Oxford Industries, Inc. (OXM) Q4 2025 Earnings Call Transcript
Oxford Industries, Inc. (OXM) Q4 2025 Earnings Call Transcript
...keep reeding on seekingalpha.com
Dubai crude's premium slump as sellers pile offers onto TotalEnergies
Spot premium for Dubai crude slumped by more than half to hit its lowest level in three weeks as more sellers emerged and piled on offers while TotalEnergies remain the sole bidder, according to traders and data collated by Reuters.
...keep reeding on reuters.com
Intuit's Collapse Created A Rare Buying Window
Intuit is now rated a 'Buy' for the first time in seven years, following a significant 44% stock decline and improved valuation metrics. INTU's Q2/26 results showed 17.4% revenue growth and 48.5% EPS growth, with management guiding for 12–13% revenue and 13–15% EPS growth in FY26. Despite GenAI competitive threats, the company's proprietary data, regulatory barriers, and customer trust provide strong competitive advantages and protect core businesses.
...keep reeding on seekingalpha.com
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit
NEW YORK, March 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the "Class Period"), of the important April 21, 2026 lead plaintiff deadline. So what: If you purchased Corcept common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on prnewswire.com
CIGL Investors Have Opportunity to Lead Concorde International Group Ltd. Securities Fraud Lawsuit
NEW YORK, March 26, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Concorde International Group Ltd. (NASDAQ: CIGL) between April 21, 2025 and July 14, 2025, inclusive (the "Class Period").
...keep reeding on prnewswire.com
New Data Reveals the Interview Questions That Cause the Most Candidate Anxiety - And How AI Is Changing That
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- After reviewing patterns across thousands of candidate sessions, LockedIn AI found that interview anxiety isn't random - it spikes around the same handful of questions, and it disproportionately punishes the candidates who prepared the most.
...keep reeding on globenewswire.com
Judge Blocks Pentagon's Attempt to Blacklist Anthropic
Federal judge finds Pentagon's effort to cut off the AI firm's access to federal contracts "likely unlawful."
...keep reeding on cnet.com
Could Buying NuScale Power Stock Today Set You Up for Life?
On paper, NuScale Power appears positioned to benefit from renewed appreciation for nuclear power as a clean energy source. However, other factors signal why shares have fallen by 80% and why a 5x to 10x move higher could prove challenging.
...keep reeding on fool.com
2026 Taipei Cycle Show: MOEA and CHC Spearhead Dual Transition Toward Smart Connectivity and Net-Zero Sustainability
/PRNewswire/ -- The 2026 Taipei Cycle Show officially kicked off this March, serving as a premier global hub for cycling. Taiwan is signaling a bold new era
...keep reeding on prnewswire.com
EeasyTile Wholesale Limited Announces Launch of Emotionally Inspired Home Tile Collection
HONG KONG, March 27, 2026 (GLOBE NEWSWIRE) -- EeasyTile Wholesale Limited today announced the launch of a new home tile collection designed to integrate functional performance with emotionally uplifting design elements. The product line introduces an approach that blends aesthetic appeal with mood-supportive qualities across a range of porcelain, ceramic, textured, and large-format surfaces.
...keep reeding on globenewswire.com
PAYSAFE DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Paysafe Limited Investors to Secure Counsel Before Important April 7 Deadline in Securities Class Action - PSFE
New York, New York--(Newsfile Corp. - March 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Paysafe Limited (NYSE: PSFE) between March 4, 2025 and November 12, 2025, inclusive (the "Class Period"), of the important April 7, 2026 lead plaintiff deadline. SO WHAT: If you purchased Paysafe securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
...keep reeding on newsfilecorp.com
Gelatine Sculpt Claims Evaluated: Documenting the Gelatin Trick Recipe Investigation for Consumer Safety
Largo, FL, March 26, 2026 (GLOBE NEWSWIRE) -- This content contains affiliate links. If a purchase is made through these links, a commission may be earned at no additional cost to the buyer. This is an informational overview and does not constitute medical, health, or dietary advice.
...keep reeding on globenewswire.com
Why the Class of 2025 Refuses to Interview Without AI After Watching a Generation Get Laid Off
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- LockedIn AI has seen a surge of early-career candidates turning to real-time interview assistance - not as a shortcut, but as a survival strategy in a job market that has left them with almost no margin for error.
...keep reeding on globenewswire.com
Sungrow et le groupe ENEVO signent un accord historique de stockage d'énergie de 1 GWh pour alimenter la transition énergétique en Roumanie
/PRNewswire/ -- Sungrow, leader mondial des onduleurs photovoltaïques et des systèmes de stockage d'énergie (SSE), a annoncé la signature d'un accord
...keep reeding on prnewswire.com
Domino's Pizza Group: Shares Remain Cheap Amid Ongoing Macro Woes
I continue to rate Domino's Pizza Group plc "Strong Buy", with its price-to-earnings valuation and dividend yield both at historically attractive levels. Amid ongoing macro headwinds, system sales rose 1.5% last year. Volume growth was negative, though, and this is a bigger driver of the firm's earnings. Declining store-level profitability has weighed on store count growth, though unit economics remain robust, which should power expansion in the long run.
...keep reeding on seekingalpha.com
Sungrow Announces 1,155 MWh C&I BESS Partnership in South Africa
/PRNewswire/ -- Sungrow, the global leading PV inverter and energy storage system (ESS) provider, has signed a landmark agreement with Herholdt's Group, its
...keep reeding on prnewswire.com
Microsoft, Meta, and Alphabet Stocks Are All Getting Hammered. But I Think Only 1 Is Worth Buying
Microsoft's cloud computing segment is trailing Alphabet's in growth, while its core software business faces a tricky transition to an AI-driven world. Meta remains heavily tethered to its social media roots, and its slowing earnings growth is concerning ahead of its heavy 2026 infrastructure build-out.
...keep reeding on fool.com
National Afterschool Association Recognizes Think Together's Sara Orellana Among 2026 Next Generation of Afterschool Leaders
/PRNewswire/ -- Think Together, California's largest nonprofit expanded learning service provider, is proud to announce Family and Community Engagement (FACE)
...keep reeding on prnewswire.com
Why Navan Stock Soared Today
Navan's AI assistants can schedule trips and automate expense reports. The company's profitability is rapidly improving as its sales surge.
...keep reeding on fool.com
Recession Risks Are Rising According To Wall Street. Here's What It Means for Investors.
Blame rising oil prices.
...keep reeding on fool.com
Balchem: An Attractive Valuation Makes This Stock A Buy
Balchem delivered strong Q4 results, with revenue up nearly 10% year-over-year and all segments posting growth. BCPC boasts a 17-year streak of double-digit dividend hikes, supported by a payout ratio consistently below 20%. The stock trades at a roughly 25% discount to its estimated fair value, with robust forward return potential exceeding 14%.
...keep reeding on seekingalpha.com